Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies – MDPI – 2019

Publicação
jul. 26, 2022

This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.

Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab

Publicação
ago. 09, 2021

Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.

HYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION

Publicação
jun. 15, 2021

The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.

International standardization of CDT measurement

Publicação
jun. 15, 2021

IFCC CDT-Working Group standardized the CDT measurement.

Carbohydrate-deficient transferring testing: a truly traceable and specific biomarker for chronic alcohol misuse

Publicação
jun. 15, 2021

Article from Jean Deenmamode, IFCC CDT working group chair in CLI magazine.

2017 Mc Donald Criteria for multiple sclerosis diagnosis

Publicação
jun. 15, 2021

2017 Mc Donald Criteria for multiple sclerosis diagnosis includes CSF IgG oligoclonal bands.

2005 Multiple Sclerosis Consensus Criteria

Publicação
jun. 15, 2021

2005 Multiple sclerosis consensus criteria includes CSF IgG oligoclonal bands.

Effects of hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by twelve methods

Publicação
jun. 14, 2021

Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results depending on the method of analysis used. Therefore, it is important to know the limitations of the method used for HbA1c determination.